相关实验视频

Updated: May 11, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

L-741626通过向Ref-1来抑制MAPK/ERK信号通路活动来抑制肝细胞癌的进展

Shuiling Jin^1,2, Qi Zhao^3,4, Xiao Sun⁴

¹Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. fccjinsl@zzu.edu.cn.

|April 16, 2025

概括

一种新的化合物L-741626通过向氧化还原因子1 (Ref-1) 和MAPK/ERK通路,有效地抑制肝细胞癌 (HCC) 的生长. 它还抑制了瘤茎,增强了索拉芬尼治疗HCC的疗效.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

肝细胞癌 (HCC) 是一个重大的临床挑战,晚期癌症对当前疗法反应有限.
针对瘤生长的新型小分子化合物对于推进癌症研究和治疗至关重要.
瘤干细胞有助于抵抗已建立的HCC疗法,如 sorafenib.

研究的目的:

研究新型化合物L-741626.6的抗HCC作用.
阐明L-741626的作用背后的分子机制,包括其信号通路的目标.
评估L-741626在HCC的联合治疗中的潜力.

主要方法:

进行了体内和体外实验,以评估L-741626对HCC生长的影响.
分子对接和药物亲和度测试确定了氧化还原因子1 (Ref-1) 作为一个关键目标.
研究了Ref-1,CRAF和MAPK/ERK通路之间的相互作用,以及L-741626对瘤干的作用.

主要成果:

L-741626通过抑制MAPK/ERK信号通路,显著抑制HCC生长.
在HCC中过度表达的Redox因子1 (Ref-1) 被确定为L-741626.6的直接标.
L-741626抑制了瘤干,并与索拉费尼布表现出协同效应,增强了抗瘤活性.

结论:

L-741626代表了一种针对HCC的新型治疗剂,向Ref-1并抑制MAPK/ERK信号传递.
该化合物的抑制瘤干的能力提供了一种克服索拉芬尼布耐药性的策略.
使用L-741626和索拉芬尼的联合治疗显示出改善HCC治疗结果的前景.

关键词:

肝细胞癌是肝细胞癌.L-74162626 的时间在MAPK/ERKK中.降氧因子 1 1 索拉费尼布 (Sorafenib) 是一种

更多相关视频

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

相关概念视频

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...